Follow up
toxicity
RECURRENT DISEASE
Eligible patients will continue treatment unless there is evidence of recurrent disease, unacceptable toxicity or withdrawal of consent from the study. Following completion of adjuvant treatment, patients will undergo longitudinal blood tests for ctDNA every 3 months for the first year post-surgery, every 6 months for years 2 and 3, and annually for years 4 and 5, with computer tomography (CT) imaging performed at the end of years 1, 2 and 3 (Fig. Follow up schedule for blood sample collection and CT imaging